title: Transcatheter aortic valve replacement: The year in review 2016.
abstract: Transcatheter aortic valve replacement (TAVR) continued to make major strides in 2016, simultaneously expanding its application to lower risk patients as well as more technically challenging subsets of patients with aortic stenosis (AS). The two major accomplishments this year were the establishment of TAVR as the preferred treatment strategy over surgical aortic valve replacement (SAVR) in intermediate risk patients, and initial signals that TAVR and SAVR may be clinically equivalent in low-risk populations. Meanwhile, there is continued expansion of TAVR to challenging clinical subsets (bicuspid aortic valve [BAV], patients with concomitant advanced coronary artery disease [CAD], and failed surgical bioprostheses), and encouraging initial experiences with newer transcatheter heart valve systems. This paper summarizes the major research studies published on TAVR in 2016.
authors.affiliation: Geisinger Clinic, Pearsall Heart Hospital, Wilkes-Barre, Pennsylvania.
authors.forename: Kishore J
authors.identifier: http://orcid.org/0000-0001-9441-296X
authors.initials: KJ
authors.lastname: Harjai
authors.affiliation: Detroit Medical Center, Detroit, Michigan.
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Grines
authors.affiliation: Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
authors.forename: Jean-Michael
authors.initials: JM
authors.lastname: Paradis
authors.affiliation: Columbia University Medical Center, New York, New York.
authors.forename: Susheel
authors.initials: S
authors.lastname: Kodali
mesh_terms: D001024:Aortic Valve Stenosis / Q000601:surgery*; D006801:Humans; D065467:Transcatheter Aortic Valve Replacement
keywords: TAVR; aortic valve; aortic valve replacement; cardiology; transcatheter